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BACKGROUND
The effects o f  lung transplantation on the survival and quality o f  life in children 
with cystic fibrosis are uncertain.
METHODS
We used data from the U.S. Cystic Fibrosis Foundation Patient Registry and from 
the Organ Procurement and Transplantation Network to identify children with 
cystic fibrosis who were on the waiting list for lung transplantation during the 
period from 1992 through 2002. We performed proportional-hazards survival model­
ing, using multiple clinically relevant covariates that were available before the chil­
dren were on the waiting list and the interactions o f  these covariates with lung 
transplantation as a time-dependent covariate. The data were insufficient in quality 
and quantity for a retrospective quality-oflife analysis.
RESULTS
A total o f  248 o f  the 514 children on the waiting list underwent lung transplanta­
tion in the United States during the period from 1992 through 2002. Proportional- 
hazards modeling identified four variables besides transplantation that were asso­
ciated with changes in survival. Burkholderia cepacia infection was associated with a 
trend toward decreased survival, regardless o f whether the patient underwent trans­
plantation. A diagnosis o f  diabetes before the patient was placed on the waiting list 
decreased survival while the patient was on the waiting list but did not decrease 
survival after transplantation, whereas older age did not affect waiting-list survival 
but decreased post-transplantation survival. Staphylococcus aureus infection increased 
waiting-list survival but decreased post-transplantation survival. Using age, diabetes 
status, and S. aureus infection status as covariates, we estimated the effect o f  trans­
plantation on survival for each patient group, expressed as a hazard factor o f less than 
1 for a benefit and more than 1 for a risk o f harm. Five patients had a significant 
estimated benefit, 283 patients had a significant risk o f  harm, 102 patients had an 
insignificant benefit, and 124 patients had an insignificant risk o f  harm associated 
with lung transplantation.
CONCLUSIONS
Our analyses estimated clearly improved survival for only 5 o f  514 patients on the 
waiting list for lung transplantation. Prolongation o f life by means o f lung transplan­
tation should not be expected in children with cystic fibrosis. A prospective, random­
ized trial is needed to clarify whether and when patients derive a survival and quality- 
oflife benefit from lung transplantation.
N ENGL J MED 357;21 WWW.NEJM.ORG NOVEM BER 22, 2007
From the Departments of Internal Medi­
cine (T.G.L., B.C.C.}, Mathematics (F.R.A.j, 
Biology (F.R.A.5, and Pediatrics (T.G.L.5, 
and the Intermountain Cystic Fibrosis 
Center (T.G.L.5 and the Lung Transplant 
Program (B.C.C), University of Utah, Salt 
Lake City; and Nuffield College, Oxford, 
United Kingdom (D.R.C.j. Address reprint 
requests to Dr. Liou at the Division of Re­
spiratory, Critical Care, and Occupational 
Pulmonary Medicine, 26 N. Medical Dr., 
Salt Lake City, UT 84132, or at ted.liou® 
utah.edu.
N Engl J Med 2007;357:2143-52.
Copyright © 2007 Massachusetts Medical Society.
2 1 4 3
Downloaded from www.nejm.org at UNIV OF UTAH ECCLES on May 13, 2009
Copyright © 2007 M assachusetts Medical Society. All rights reserved.
T h e  N E W  E N G L A N D  J O U R N A L  o f  M E D I C I N E
1 " " ^  ND-STAGE LUNG DISEASE CAUSES ABOUT 
80% o f all deaths among patients with cys­
tic fibrosis.1 The median age at death is ap­
proximately 25 years.1 Every year, many children 
with cystic fibrosis die from respiratory failure.
Lung transplantation is the most aggressive 
therapy available for end-stage lung disease, and 
cystic fibrosis is the most frequent indication for 
lung transplantation in children.2 This high-risk 
procedure is costly, and the associated effect on 
the patient’s quality o f life is uncertain. Compli­
cations associated with transplantation account 
for 12% of all deaths among patients with cystic 
fibrosis, making transplantation the second lead­
ing cause o f death after end-stage lung disease.1
Several retrospective studies have evaluated the 
survival benefit o f lung transplantation for pa­
tients with cystic fibrosis.3'7 An analysis o f data 
from 124 children with cystic fibrosis referred 
for lung transplantation, including 47 children 
who underwent the procedure at the Great Or­
mond Street Hospital in the United Kingdom 
during the period from 1988 through 1998, 
showed improved survival.6 More recently, our 
analysis o f data from 205 children who underwent 
transplantation and 1018 children who did not 
undergo transplantation from the United States 
showed no survival benefit.7
Possible explanations for the discrepancy be­
tween these findings include differences in pa­
tient characteristics, patient-selection policies, and 
transplantation and analytic methods.8’9 To ad­
dress some of the issues, we analyzed a large data 
set o f children with cystic fibrosis who under­
went lung transplantation. We used proportional- 
hazards modeling with time-dependent covari- 
ates to consider the effects o f multiple covariates 
before and after transplantation.10'13
M E T H O D S
PATIENTS
We used data from the Cystic Fibrosis Foundation 
Patient Registry (CFFPR), which includes longitu­
dinal information on patients from 117 certified 
cystic fibrosis centers during the period from 
1992 through 2002. We also used data from the 
Organ Procurement and Transplantation Network 
(OPTN) from 1988 through 2004. The OPTN data 
include information on all patients ever placed on 
the waiting list for lung transplantation in the 
United States. We matched and verified patients
between these data sets using patient-specific 
identifiers, and we examined each match for con­
firmation.
Our project was reviewed and approved by the 
investigational review board o f the University of 
Utah, the Cystic Fibrosis Foundation, and the 
OPTN. Informed consent specific to this study 
was not required.
STUDY DESIGN
Because children who underwent lung transplan­
tation were previously on the waiting list, we could 
not directly compare the survival o f patients on 
the waiting list with the survival o f patients after 
transplantation using, for example, Kaplan-Meier 
statistics. However, with the use o f proportional- 
hazards methods with transplantation as a co- 
variate that changed at the time o f transplanta­
tion, we could estimate how the procedure altered 
the risk o f death.10’12 The modeling o f transplan­
tation as a time-dependent covariate was intro­
duced in 1977 to analyze the effects o f heart 
transplantation on survival.11 In the present study, 
we analyzed lung transplantation as a time-depen­
dent covariate. We derived hazard factors that re­
veal the associated multiplicative change in the 
risk of death due to lung transplantation. Detailed 
modeling procedures are described in the Sup­
plementary Appendix, available with the full text 
o f this article at www.nejm.org.
STATISTICAL ANALYSIS
Using three different methods, we tested for a de­
parture from the proportional-hazards assump­
tion that the effect o f an explanatory variable on 
the hazard is constant in time.14 First, with the 
use o f S-plus 7.0 software (Insightful), we applied 
the S-plus procedure called cox.zph to the final 
model. Second, we separated study patients into 
two roughly equal groups according to the year of 
their placement on the waiting list (during the pe­
riod from 1992 through 1998 or from 1999 through 
2002), and we compared the resulting proportion­
al-hazards models with each other and with the 
final model. Finally, we tested for the effects of 
higher mortality immediately after transplantation3 
by introducing a time-dependent covariate10 for 
survival beyond the first 6 months after transplan­
tation.
We performed two additional tests o f model 
stability. We examined the effect o f loss to follow- 
up15 in our final model (see the Supplementary
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Appendix), and we applied bootstrapping tech­
niques on our final model to rule out the possi­
bility that a small number o f patients with un­
usual characteristics accounted for the results o f  
our analysis.16
We examined potential markers o f quality o f  
life, including days o f  hospitalization and com­
plications o f  disease per year. For this analysis, 
we compared values in the year before transplan­
tation with those 1 and 2 years after transplanta­
tion among surviving patients.
RESULTS
PATIENTS
The CFFPR for the period from 1992 through 
2002 contains data on 31,394 patients with cystic 
fibrosis. The OPTN has data for 21,679 patients 
who were on the waiting list during the period 
from 1988 through 2004. We identified 3364 pa­
tients with cystic fibrosis who were placed on the 
Iung-transplantation waiting list during the pe­
riod from 1992 through 2002; 602 o f these pa­
tients were younger than 18 years o f  age. We ex­
cluded 10 patients for whom Iung-function data 
were not available, 2 patients with missing mi­
crobiologic data, 4 patients with missing data 
regarding acute exacerbations, 2 patients with 
recorded death dates that preceded their place­
ment on the waiting list, and 70 patients with 
missing data during the 2 years before placement 
on the waiting list. After these patients had been 
excluded, there were 514 patients, or 85% of all 
children with cystic fibrosis listed for transplan­
tation in the United States during the study period. 
The median survival for patients who died before 
transplantation was 223 days. The median time 
to transplantation for the 248 patients who under­
went transplantation was 427 days. The median sur­
vival after transplantation was 1260 days (Fig. 1).
DEATHS
A total o f 141 patients who were on the waiting 
list died, and 120 patients died after undergoing 
transplantation (Table 1). Respiratory failure 
caused 91% o f the deaths among patients who 
were on the waiting list. After transplantation, 
60% of deaths were due to complications o f trans­
plantation (primarily allograft rejection), 29% of  
deaths were due to respiratory failure, and 11% 
o f deaths were due to other causes.
PROPORTIONAL-HAZARDS MODELING
We began to develop our model with 26 covari­
ates and their interaction terms with transplanta­
tion (see Table A in the Supplementary Appendix). 
Backward selection resulted in a final model with 
four covariates besides lung transplantation and 
three interaction terms. Tests o f the proportional- 
hazards assumption did not show a departure 
from proportionality.10’12’14 Results were not af­
fected by the method o f determining loss to fol- 
Iow-up for the 85 patients on the waiting list who 
did not undergo transplantation before the end o f  
the study and the 128 patients who were alive at 
the end o f the study. The coefficients and calcu­
lated hazard factors were shown to be robust with 
bootstrapping.16
To facilitate interpretation, we recoded inter­
action terms to isolate effects before and after 
transplantation, thus revealing how covariate e f  
fects changed with this procedure (Table 2).12’13 
Older age at study entry was associated with 
improved survival before transplantation but de­
creased survival after transplantation. Diabetes 
in patients before study entry was associated with 
reduced survival before transplantation but was 
not significantly associated with survival after 
transplantation. Staphylococcus aureus infection was
No. at Risk 248
Years since Transplantation
164 117 83 59
Figure 1. Survival after Lung Transplantation among 248 Children with Cystic 
Fibrosis Who Were Younger than 18 Years of Age.
The Kaplan-Meier curve (solid black line) is shown along with the upper 
and lower 95% confidence limits (dashed blue lines). The median survival of 
these patients was 3.45 years (1260 days). The confidence limits shown here 
match those reported by Aurora et al.6 The rate of survival at 5 years was 
39.5% — insignificantly less than the 46.9% reported by the Organ Procure­
ment and Transplantation Network for all recipients of lung transplants for 
cystic fibrosis.2
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Patients Who Did Not 
Receive Transplants 
(N =266) P Value
Age — yr 0.36
Median 14.63 14.31
Range 6.01 to 17.99 6.39 to 17.95
Female sex — % 56.4 61.3 0.30
Deaths — no. (%) 120 (48.4) 141 (53.0) 0.17
FEV, — % of predicted valuef 32.7±10.8 35,1±11.9 0.006f
Acute exacerbations — no. 0.35
Mean 2.73 2.58
Range 0 to >5 Oto >5
Weight for age — z score -1.80±0.90 -1.75±0.91 0.63
Pancreatic sufficiency — % 1.6 1.8 0.91
Diabetes — %% 6.8 12.0 0.11
Burkholderia cepacia infection — % 7.7 5.3 0.26
Staphylococcus aureus infection — % 35.5 27.0 0.11
5-yr predicted survival — %f 0.78
Mean 57.0±20.0 56.9±20.3
Range 8.3 to 95.2 12.6 to 98.8
* Plus-minus values are means ±SD. Patients who did not receive transplants are those who did not receive a transplant 
before the end of the study.
f  The proportional-hazards method of analyzing survival corrects for significantly different covariates among study patients 
— in this case, for a significant difference in the forced expiratory volume in 1 second (FEVl) between transplant recipi­
ents and patients who did not receive a transplant.
:j: Patients with diabetes were identified by the use of insulin.
|  The 5-year predicted survival was calculated on the basis of age, sex, FEV^, weight-for-age z score, diabetes status, 
pancreatic sufficiency status, S. aureus infection and B. cepacia infection status, number of acute exacerbations of cystic 
fibrosis within 1 year, and an interaction term between B. cepacia and the number of acute exacerbations. The predicted 
survival was calculated from the date of the last clinic visit before the patient’s placement on the waiting list for trans­
plantation.4^ 7
associated with improved survival before trans­
plantation but with greatly reduced survival after­
ward. Burkholderia cepacia infection did not modify 
the effect o f  transplantation, but it has previously 
been associated with decreased survival for af­
fected patients,4’5 and is associated with a trend 
toward decreased survival in this population.
Porward-selection procedures were used to re­
consider the effects o f lung function expressed as 
the percent o f  the predicted value for forced expi­
ratory volume in 1 second (PEV^ /o) and infections 
with Achromobacterxylosoxidans, methicillin-resistant
S. aureus, Stenotrophomonas maltophilia, Pseudomonas 
aeruginosa, mucoid P. aeruginosa, and other pseudo­
monas species. None o f the results were signifi­
cant. Using the calendar date o f  transplantation, 
we found some suggestion, short o f statistical sig­
nificance, that survival prospects decreased in the
later years o f  the study (see Table B in the Sup­
plementary Appendix). To determine specifically 
whether the effects o f the patient’s age on the out­
come o f transplantation persist into adulthood, 
we applied the final candidate model to the 2744 
adults with cystic fibrosis whom we identified. We 
found no interaction o f age with transplantation 
(see Table C in the Supplementary Appendix).
Values for the partial pressure o f  carbon diox­
ide in arterial blood (PaC02) were available for 
only 299 o f the 514 children studied; thus, this 
covariate was excluded from the main analysis in 
order to preserve statistical power and avoid bias. 
In a subgroup analysis, PaC02 did not have a 
significant effect on survival. Similarly, results of 
the patient’s 6-minute walk test and serum cre­
atinine level and hospitalization status had no e f  
feet. Dependence on supplemental oxygen seemed
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Table 2. Hazard Factors for Covariates affecting Survival before and after Lung Transplantation.*
No. of Hazard Robust Standard
Variable Patients Factor Coefficient Errorj" P Value
All patients 514
Burkholderia cepacia infection 1.43 0.36 0.23 0.12
Patients before transplantation 514
Age (per yr) 0.97 -0.03 0.03 0.26
Diabetes 1.93 0.66 0.26 0.01
Staphylococcus aureus infection 0.69 -0.38 0.19 0.05
Patients after transplantation 248
Age (peryr) 1.13 0.12 0.03 <0.001
Diabetes 0.73 -0.31 0.42 0.46
S. aureus infection 1.51 0.41 0.20 0.04
* Hazard factors for covariates were used to calculate the proportional hazard for death associated with lung transplanta­
tion. Because the effects of age, diabetes, and S. aureus infection depend on transplantation status, a single hazard fac­
tor for lung transplantation that applies to every patient cannot be calculated. However, a hazard factor for lung trans­
plantation can be calculated with the use of the covariate values for each patient with the following formula:
g0.119Age-0.312d-J-0.410s-1.728 
-  e-0.0323Age+0.657d-0.376s
In this equation, HF denotes the estimated hazard factor for death after lung transplantation and is derived from divid­
ing the hazard factor for death after transplantation (the top term in the fraction) by the hazard factor before transplan­
tation (the bottom term in the fraction). Because of the absence of interactions with transplantation, terms for B. cepa­
cia infection cancel out. In the equation, age is the age of the patient at the time of the last clinic visit before placement 
on the waiting list for transplantation, d equals 1 for patients with diabetes and 0 otherwise, and s equals 1 for patients 
with S. aureus infection and 0 otherwise. The final term in the numerator reflects the baseline hazard associated with 
post-transplantation status. Results apply only to children with cystic fibrosis. We excluded adults with cystic fibrosis 
from the present study, and we included no patients with end-stage lung disease that was not due to cystic fibrosis, 
f  The calculation of the robust standard error for each coefficient uses an approximate jackknife estimate of the variance.
to decrease survival. However, oxygen use was in­
consistently recorded when we compared CFFPR 
and OPTN data, so that the magnitude and sig­
nificance o f the result were uncertain. Poorer 
functional status was associated with decreased 
survival among patients for whom data on func­
tional status were available but did not have an 
interaction with transplantation. Data on pulmo- 
nary-artery pressure were sparse, and the num­
ber o f patients requiring mechanical ventilation 
at the time o f placement on the waiting list was 
too small to perform a meaningful analysis.
MODEL INTERPRETATION
Recoding covariates with interactions12’13 im­
proves an understanding o f covariate effects, but 
understanding the clinical effect o f lung trans­
plantation requires adaptation o f the model as 
far as feasible to individual circumstances.8 Cal­
culation of transplantation hazard factors accord­
ing to age, diabetes status, and S. aureus infection 
status at the time o f placement on the waiting list 
for each of the 514 children in the study showed
hazard factors in four categories: significant es­
timated benefit (5 patients), significant risk o f  
harm (283 patients), insignificant benefit (102 pa­
tients), and insignificant risk of harm (124 patients) 
(Fig. 2A). The distribution of estimated effects was 
similar for the 248 patients who underwent trans­
plantation: 1 patient for whom transplantation was 
estimated to be beneficial, 145 for whom it was 
estimated to be harmful, and 102 for whom ben­
efit was indeterminate (Fig. 2B).
Because our patients had a wide range o f lung 
function and prognoses, we examined results for 
patients categorized according to FEV /^o17 and 
5-year predicted survival.5’7 We found no thresh­
old o f FEV1% or 5-year predicted survival below 
which the hazard factor for death associated with 
transplantation was generally reduced (Fig. 3).
QUALITY OF LIFE
We examined the data for changes in the number 
o f days o f hospitalization, number o f complica­
tions, and incidence o f bronchiolitis obliterans. 
After transplantation, the number o f days o f hos-
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pitalization appeared to decrease, but complica­
tions appeared to increase, resulting in uncertain 
implications for quality o f  life (see Pig. A in the 
Supplementary Appendix). Reporting biases, es­
pecially lack o f reporting o f bronchiolitis obliter­
ans, further reduced the applicability o f  these 
findings (see the Supplementary Appendix).
D I S C U S S I O N
This retrospective study o f children with cystic 
fibrosis who were selected for lung transplanta­
tion showed that most o f the children (509 o f the 
514 studied and 247 o f the 248 patients who un­
derwent transplantation) did not derive a sig­
nificant estimated survival benefit. Although the 
majority o f patients (283) were at significant risk 
for harm, for 226 patients, the procedure was not 
clearly harmful or beneficial. Less than 1% of  
patients had a significant estimated survival ben­
efit (Pig. 2). In contrast to earlier studies examin­
ing primarily adults with cystic fibrosis,5’7 there 
was no lower threshold o f  5-year predicted sur­
vival4 below which children with cystic fibrosis 
had an estimated survival benefit due to lung 
transplantation. Similarly, there was no such low­
er threshold for PEV^ /o (Pig. 3).
Our results reflect essentially the entire U.S. 
experience with pediatric lung transplantation 
for cystic fibrosis during the period from 1992 
through 2002. Actuarial survival for lung trans­
plantation for cystic fibrosis has not appreciably 
changed in the past several years2; thus, the abil­
ity o f our model to predict survival outcomes for 
patients undergoing transplantation after 2002 is 
likely to be high.
On the basis o f results o f proportional-hazards 
modeling (Table 2), children with cystic fibrosis 
could be categorized into four clinically identifi­
able groups that varied according to the outcome 
o f lung transplantation (Pig. 2). Within each 
group, outcomes o f transplantation worsened with 
increasing age, but the effect o f  age disappeared 
for patients who were 18 years o f  age or older 
(see Table C in the Supplementary Appendix).
Children who were infected with S. aureus and 
children who were 12 years o f  age or older were 
highly likely to be harmed, whereas younger chil­
dren with S. aureus infection had no clear benefit 
or risk o f harm from transplantation. The results 
(Table 2) confirmed previous results that showed 
that S. aureus infection improves survival among
Figure 2 (facing page). Estimated Hazard Factors 
Due to Lung Transplantation.
Panel A shows the estimated hazard factors due to lung 
transplantation calculated for each of the 514 patients in 
the study, plotted as a function of age. Blue symbols de­
note the lack of power to determine a significant risk of 
harm or benefit from transplantation. Red symbols de­
note a significant risk of harm, and orange symbols a 
significant benefit. Patients are grouped according to 
four curves that correspond to the presence of either, 
both, or neither of the binary variables (S. aureus infec­
tion and diabetes). The variable of B. cepacia infection 
does not interact with transplantation. The value of each 
hazard factor and the level of significance of each factor 
within each group at both extremes of age, where the 
data are sparse, should be viewed with caution, since 
they may have been the result of overextrapolation of 
the data. Unfortunately, all five of the patients with an 
apparently significant decrease in hazard factors (or­
ange symbols) were included in this uncertain category. 
Panel B shows the estimated hazard factors due to lung 
transplantation for the 248 patients who underwent the 
procedure during the study period. These hazard factors 
are plotted as a function of age. Blue symbols denote 
the lack of power to determine a significant risk of harm 
or a significant benefit from transplantation. Red sym­
bols denote a significant risk of harm, and orange sym­
bols denote a significant benefit. A significant decrease 
in the hazard factor (orange symbol) is apparent for only 
one patient.
patients with cystic fibrosis who have not un­
dergone transplantation.4 The protective effect of
S. aureus infection is most likely due to active com­
petition between S. aureus and more harmful 
P. aeruginosa organisms in the airways o f patients 
with cystic fibrosis (unpublished data). After 
transplantation, S. aureus infection was nearly as 
hazardous as B. cepacia infection (Table 2), per­
haps as a side effect o f immunosuppression.
The two youngest patients with diabetes may 
have had a significant survival benefit with trans­
plantation, whereas the remaining patients had 
no clear change in survival. The absence o f  high 
hazard factors suggesting harm may reflect the 
tendency for diabetes to develop in these patients 
after transplantation. In essence, patients with 
diabetes have already paid some o f the cost of 
transplantation and thus are less likely to be 
harmed (Pig. 2A). O f the 15 children with both
S. aureus infection and diabetes, none had a sig­
nificant benefit from transplantation.
Among 318 children with neither S. aureus 
infection nor diabetes, 165 were at risk for de­
creased survival, 3 appeared to have had a sig-
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A AH Study Patients
6-1
Patient groups
A Staphylococcus aureus, N=149 
V Diabetes, N=32 
O Both diabetes and S. aureus, N=15 
O Neither diabetes nor S. aureus, N=31S 
□  Coinfection with Burkholderia cepacia, N=32
P<0.05, hazard >1, N=283 
P>0.05, hazard —1, N=226 
P<0.05, hazard <1, N=5
Age at Clinic Visit (yr)






A Staphylococcus aureus, N =83 
V Diabetes, N=12 
O Both diabetes and S. aureus, N=5 
O Neither diabetes nor S. aureus, N=14S 
\~~\ Coinfection with Burkholderia cepacia, N=19
P<0.05, hazard >1, N=145 
P>0.05, hazard —1, N=102 
P<0.05, hazard <1, N=1
12 14
Age at Clinic Visit (yr)
nificant survival benefit, and the remainder had 
an uncertain effect of lung transplantation (see 
Table D in the Supplementary Appendix). How­
ever, the three patients with a survival benefit were 
at the extreme younger end o f the age spectrum, 
where there were relatively fewer data, raising the
concern that the estimated benefit results from 
the overextrapolation o f data rather than a real 
reduction in hazard (Fig. 2A).
Many studies have analyzed the survival effects 
o f multiple covariates besides lung transplanta- 
tion.3’5-7’11’18’19 However, this study identifies co-
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Figure 3. Estimated Hazard Factors for the 514 Patients in the Study According to Clinical Status.
Panel A shows the estimated hazard factors calculated as a function of the percent of the predicted value for forced 
expiratory volume in 1 second, but the data have been arranged as a series of nine scatter plots in order 
to identify strata. Panel B shows the estimated hazard factors as a function of the 5-year predicted survival probabil­
ity,4 expressed as the percent likelihood of survival for 5 years after the date of the last clinic visit before placement 
on the waiting list. The data are arranged as a series of nine scatter plots in order to identify 5-year predicted surviv­
al strata. The hazard factor has no relationship with the 5-year predicted survival (P = 0.87), but it decreases signifi­
cantly with the FEN/,% (P<0.001). Patients with higher lung function appeared to have less harmful outcomes from 
lung transplantation, perhaps because of a significant decrease in the FEV,% with age. Neither FEV,% nor the 
5-year predicted survival probability is helpful for selecting patients who are likely to have a benefit from lung trans­
plantation from among children with cystic fibrosis who have already been selected for the waiting list.
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variates that create different effects depending on 
transplantation status, which is the key issue for 
determining the appropriateness o f transplanta­
tion. In the presence o f such effects, individual 
characteristics determine the effect o f transplan­
tation, and it becomes possible to estimate the 
effect o f transplantation for precise clinical cir­
cumstances (Pig. 2) instead of having to rely on 
a single generalized estimate (see Table E in the 
Supplementary Appendix).3’6
Our study of children with cystic fibrosis most 
closely resembles the study by Aurora et al.6 but 
our results suggesting that a survival benefit of  
lung transplantation is unlikely are seriously dis­
crepant. Reconciling the discrepancy requires con­
sideration o f differences in analytic methods, 
methods of calculating survival after transplanta­
tion, characteristics o f the patients studied, and 
waiting-list management. However, this study in­
volved four times as many patients and transplant 
recipients as those in the study by Aurora et al.; 
this affords our study much more statistical power 
(see the Supplementary Appendix).
The retrospective nature of our study raises the 
possibility of biases in patient selection for trans­
plantation. The proportional-hazards model cor­
rects for these biases, provided that there are no 
unobserved patient characteristics with a sub­
stantial effect both on the decision to undergo 
transplantation and on survival. If, for example, 
healthier patients generally waited longer for 
transplantation, the results would appear to be 
biased against transplantation.
Our analysis involved children with cystic fi­
brosis who were already selected for lung trans­
plantation, a subgroup that may not be represen­
tative o f patients with cystic fibrosis and severe 
lung disease. In the United States, patients are 
selected to undergo transplantation because of 
low lung function, increasing numbers o f exacer­
bations, and other factors that may indicate a 
poor prognosis.17’20’21 The use o f these specific 
factors to choose patients may explain the ab­
sence o f FEV /^o and weight from the model 
(Table 2) as well as the absence o f a significant 
association between PaC02 and outcomes. Thus, 
our ability to derive selection criteria for trans­
plantation with broad applicability among chil­
dren with cystic fibrosis might have been limited. 
Nevertheless, the finding that only 1 o f 248 chil­
dren with cystic fibrosis who underwent trans­
plantation during the period from 1992 through 
2002 had clearly improved survival (Pig. 2B) sug­
gests that the factors used to select candidates 
for transplantation could not identify patients 
who were likely to have a survival benefit.
Our model has little similarity to the lung 
allocation score for prioritizing U.S. candidates 
for lung transplantation.22 This score determines 
the order o f transplantation for patients on the 
waiting list with several dissimilar end-stage lung 
diseases, whereas our study focused on selecting 
patients with cystic fibrosis for transplantation. 
We analyzed key variables in the CFFPRand data 
from patients younger than 12 years o f age that 
were unavailable or excluded from the develop­
ment of the lung allocation score. The OPTN will 
revise this scoring system on the basis o f accrued 
experience to improve management o f the wait­
ing list. However, management o f the list can be 
improved more effectively if  there is improved 
initial patient selection, the goal of this study.
We cannot comment on the effect o f lung 
transplantation on the quality o f life for children 
with cystic fibrosis that is so severe that they are 
considered for this procedure. Two prospective, 
cross-sectional studies o f quality of life, involving 
280 transplant recipients (61 with cystic fibrosis) 
and 108 transplant recipients (10 with cystic fi­
brosis), showed quality-of-life improvements for 
survivors.23’24 However, the benefits varied widely 
and were countered by increasing illnesses, espe­
cially bronchiolitis obliterans, a common form of 
allograft rejection, and by decreased survival. Our 
analysis o f indirect indicators o f  quality o f life 
produced mixed results o f uncertain quality (see 
the Supplementary Appendix).
The results underscore that sustained, multi­
disciplinary care rather than lung transplanta­
tion is central to longevity in children with cys­
tic fibrosis. Comprehensive, evidence-based care25 
maximizes survival and quality o f life by preserv­
ing health and avoiding transplantation. Lung 
transplantation in adulthood, i f  needed, can be 
undertaken with a greater probability of increased 
survival.7
Our results suggest several choices: continua­
tion of lung transplantation in children with cys­
tic fibrosis for potential improvement in quality 
o f life, discontinuation o f transplantation to avoid 
decreased survival, or consideration o f a prospec­
tive, randomized trial o f lung transplantation for 
children with cystic fibrosis, combined with an 
assessment o f quality o f life. The first option en­
tails permitting well-informed persons26 to seek 
uncertain quality-of-life improvement despite the
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likelihood that lung transplantation will cause 
decreased survival. The second option rules out 
the potential benefit for the sizable group o f  
patients for whom our study could not estimate 
a significant survival benefit or risk o f harm. The 
last option requires overcoming daunting logis­
tical challenges and challenges in trial design, 
especially i f  quality o f  life is included as an end 
point along with survival.26 Despite the chal­
lenges, we believe that the burden o f proof has 
shifted: a beneficial effect o f  lung transplantation 
can no longer be assumed,19 and a study is need­
ed to show a survival or quality-of-life benefit for 
a well-defined group o f children with cystic fibro­
sis. Only a prospective trial can fully address po­
tential biases, search for additional selection 
criteria, thoroughly evaluate the effect o f  trans­
plantation on quality o f life, and show the effect 
o f the procedure on survival.
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CORRECTION
Lung Transplantation and Survival in Children with 
Cystic Fibrosis
Lung Transplantation and Survival in Children with Cystic Fibrosis . 
In the Results section of the Abstract (page 2143), the third se n ­
tence, " Burkholderia cepacia infection decreased  survival, regard­
less of w hether the patient underwent transplantation," should have 
read, "Burkholderia cepacia infection w as associated  with a  trend to ­
ward decreased  survival, regardless of whether the patient underwent 
transplantation." The last sen tence  of the Results section of the Ab­
stract, ''F ive patients had a  significant estim ated benefit, 315 patients 
had a  significant risk of harm, 76 patients had an insignificant b en e ­
fit, and  118 patients had an insignificant risk of harm associa ted  with 
lung transplantation," should have read, ''F ive patients had a  signif­
icant estim ated benefit, 283 patients had a  significant risk of harm,
102 patients had an insignificant benefit, and 124 patients had an in­
significant risk of harm associated  with lung transplantation."
In the Results section of the text, under ''P a tien ts"  (page 2145), the 
last sen tence, ''T he  median survival after transplantation w as 1037 
days (Fig. 1)," should have read, ''T he  median survival after tran s­
plantation w as 1260 days (Fig. 1)." Figure 1 (page 2145) should be 
replaced by the new Figure 1, which is available in the revised ver­
sion of the article. The second, third, and fourth sen ten ces of the 
legend to the figure, which read, ''T h e  median survival of th ese  p a ­
tients w as 2.84 years (1037 days). The upper confidence limit shown 
here roughly m atches the post-transplantation Kaplan-M eier survival 
curve in the report by Aurora e t al.6 The rate of survival at 5 years 
w as 32.9%  — som ew hat less than the 46.9%  reported by the Organ 
Procurem ent and Transplantation Network for all recipients of lung 
transplants for cystic fibrosis2" should have read, ''T h e  median sur­
vival of these  patients w as 3.45 years (1260 days). The confidence 
limits shown here match those  reported by Aurora et al.6 The rate of 
survival a t 5 years w as 39.5%  — insignificantly less than the 46.9%  
reported by the Organ Procurem ent and Transplantation Network for 
all recipients of lung transplants for cystic fibrosis.2"
The first com plete sen tence  on page  2146, "Burkholderia cepacia 
infection did not modify the effect of transplantation, but it w as a s ­
sociated with decreased  survival for all affected patients," should 
have re a d , '' Burkholderia cepacia infection did not modify the effect of 
transplantation, but it has previously been associated  with d ecreased  
survival for affected patients4,5 and is associated  with a  trend toward 
d ecreased  survival in this population."
The second and third sen ten ces in ''M odel Interpretation'' (page 
2147), which read, ''Calculation of transplantation hazard factors a c ­
cording to age, d iabetes sta tus, and S. aureus infection sta tus at the 
time of placem ent on the waiting list for each  of the 514 children in the 
study show ed hazard factors in four categories: significant estim ated 
benefit (5 patients), significant risk of harm (315 patients), insignifi­
cant benefit (76 patients), and insignificant risk of harm (118 patients)
(Fig. 2A). The distribution of estim ated effects w as similar for the 248 
patients who underwent transplantation: 1 patient for whom transplan­
tation w as estim ated to be beneficial, 162 for whom it w as estim ated 
to be harmful, and 85 for whom benefit w as indeterm inate (Fig. 2B)," 
should have read, ''Calculation of transplantation hazard factors a c ­
cording to age, d iabetes status, and S. aureus infection sta tu s at the 
time of placem ent on the waiting list for each of the 514 children in 
the study show ed hazard factors in four categories: significant e s ­
tim ated benefit (5 patients), significant risk of harm (283 patients), 
insignificant benefit (102 patients), and insignificant risk of harm (124 
patients) (Fig. 2A). The distribution of estim ated effects w as similar for 
the 248 patients who underwent transplantation: 1 patient for whom 
transplantation w as estim ated to be beneficial, 145 for whom it was 
estim ated to be harmful, and 102 for whom benefit w as indeterm inate 
(Fig. 2B)."
Table 2 (page 2147) should be am ended  a s  shown. Values that have 
been changed are  shown in red.
In the Discussion section (page 2148), the second sentence, which 
read, ''A lthough the majority of patients (315) were a t significant risk 
for harm, for 194 patients, the procedure w as not clearly harmful 
or beneficial,"" should have read, ''A lthough the majority of patients 
(283) w ere at significant risk for harm, for 226 patients, the procedure 
w as not clearly harmful or beneficial."" The last sen tence  of the fifth 
paragraph, which read, ''O f the 15 children with both S. aureus infec­
tion and diabetes, none had a  significant benefit from transplantation, 
but 2 had a  significant risk of harm,"" should have read, ''O f the 15 
children with both S. aureus infection and diabetes, none had a  sig­
nificant benefit from transplantation."" The first sen tence  of the sixth 
paragraph, which read, ''A m ong 318 children with neither S. aureus 
infection nor diabetes, 192 w ere at risk for decreased  survival, 3 a p ­
peared  to have had a  significant survival benefit, and the rem ainder 
had an uncertain effect of lung transplantation,"" should have read, 
''A m ong 318 children with neither S. aureus infection nor diabetes, 
165 were at risk for decreased  survival, 3 appeared  to have had a  
significant survival benefit, and the rem ainder had an uncertain effect 
of lung transplantation.""
Table 2. [Original] Hazard Factors for Covariates Affecting Survival 
before and after Lung Transplantation.
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Original Table 2. Hazard Factors for Covariates Affecting Survival before and after Lung Transplantation.*
No. of Hazard Robust StandardVariable Patients Factor Coefficient Errory P Value
All patients 514
Burkholderia cepacia infection 1.60 0.47 0.20 0.02
Patients before transplantation 514
Age (per yr) 0.97 -0.03 0.03 0.25
Diabetes 1.94 0.6 0.27 0.01
Staphylococcus aureus infection 0.69 -0.38 0.19 0.05
Patients after transplantation 248
Age (per yr) 1.14 0.14 0.03 <0.001
Diabetes 0.80 -0.22 0.38 0.51
5. aureus infection 1.53 0.43 0.18 0.02
* Hazard factors for covariates were used to calculate the proportional hazard for death associated with lung transplan­tation. Because the effects of age, diabetes, and S. aureus infection depend on transplantation status, a single hazard factor for lung transplantation that applies to every patient cannot be calculated. However, a hazard factor for lung transplantation can be calculated with the use of the covariate values for each patient with the following formula: 
gO. 136Age-0.224d+0.428s 0.159 
e-0.033)Age+0.665d-0.375s
In this equation, HF denotes the estimated hazard factor for death after lung transplantation and is derived by divid­ing the hazard factor for death after transplantation (the top term in the fraction) by the hazard factor before trans­plantation (the bottom term in the fraction). Because of the absence of interactions with transplantation, terms for B. cepacia infection cancel out. In the equation, age is the age of the patient at the time of the last clinic visit before placement on the waiting list for transplantation, d equals 1 for patients with diabetes and 0 otherwise, and s equals 1 for patients with S. aureus infection and 0 otherwise. The final term in the numerator reflects the baseline hazard as­sociated with post-transplantation status. Results apply only to children with cystic fibrosis. We excluded adults with cystic fibrosis from the present study, and we included no patients with end-stage lung disease that was not due to cystic fibrosis.■f The calculation of the robust standard error for each coefficient uses an approximate jackknife estimate of the variance.
Table 2. [New] Hazard Factors for Covariates Affecting Survival be­
fore and after Lung Transplantation.
New Table 2. Hazard Factors forCovariates Affecting Survivalbefore and after Lung Transplantation.*
No. of Hazard Robust StandardVariable Patients Factor Coefficient Errorf P Value
All patients 514
Burkholderia cepacia infection 1.43 0.36 0.23 0.12
Patients before transplantation 514
Age (peryr) 0.97 -0.03 0.03 0.26
Diabetes 1.93 0.6 0.26 0.01
Staphylococcus aureus infection 0.69 -0.38 0.19 0.05
Patients after transplantation 248
Age (peryr) 1.13 0.12 0.03 <0.001
Diabetes 0.73 -0.31 0.42 0.46
S. aureus infection 1.51 0.41 0.20 0.04
* Red type indicates values that have been changed. Hazard factors for covariates were used to calculate the propor­tional hazard for death associated with lung transplantation. Because the effects of age, diabetes, and S. aureus infec­tion depend on transplantation status, a single hazard factor for lung transplantation that applies to every patient cannot be calculated. However, a hazard factor for lung transplantation can be calculated with the use of the covari- ate values for each patient with the following formula:
g0,119Age-0.312d+0,410s-1.728 
e-0.032)Age+0.657d-0.376s '
In this equation, HF denotes the estimated hazard factor for death after lung transplantation and is derived by divid­ing the hazard factor for death after transplantation (the top term in the fraction) by the hazard factor before trans­plantation (the bottom term in the fraction). Because of the absence of interactions with transplantation, terms for B. cepacia infection cancel out. In the equation, age is the age of the patient at the time of the last clinic visit before placement on the waiting list for transplantation, d equals 1 for patients with diabetes and 0 otherwise, and s equals 1 for patients with S. aureus infection and 0 otherwise. The final term in the numerator reflects the baseline hazard as­sociated with post-transplantation status. Results apply only to children with cystic fibrosis. We excluded adults with cystic fibrosis from the present study, and we included no patients with end-stage lung disease that was not due to cystic fibrosis.j" The calculation of the robust standard error for each coefficient uses an approximate jackknife estimate of the variance.
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